BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression

Major depressive disorder (MDD) and cocaine use disorder (CUD) are related with disability and high mortality rates. The assessment and treatment of psychiatric comorbidity is challenging due to its high prevalence and its clinical severity, mostly due to suicide rates and the presence of medical co...

Descripción completa

Detalles Bibliográficos
Autores: Fonseca, Francina|||0000-0002-0779-6545, Mestre-Pintó, Joan-Ignasi|||0000-0003-0387-9375, Rodríguez-Minguela, Rocío, Papaseit, Esther|||0000-0003-2620-4274, Pérez-Mañá, Clara|||0000-0001-6343-6918, Langohr, Klaus|||0000-0001-7075-9192, Barbuti, Margherita, Farré Albaladejo, Magí|||0000-0001-8338-7543, Torrens, Marta
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:258138
Acceso en línea:https://ddd.uab.cat/record/258138
https://dx.doi.org/urn:doi:10.3389/fpsyt.2022.836771
Access Level:acceso abierto
Palabra clave:Depression
Cocaine use disorder
Cortisol
Dual diagnosis
Brain derived neurotrophic factor (BDNF)
id ES_38ed2197e1fb34230dd9fe506e7dd67b
oai_identifier_str oai:ddd.uab.cat:258138
network_acronym_str ES
network_name_str España
repository_id_str
spelling BDNF and Cortisol in the Diagnosis of Cocaine-Induced DepressionFonseca, Francina|||0000-0002-0779-6545Mestre-Pintó, Joan-Ignasi|||0000-0003-0387-9375Rodríguez-Minguela, RocíoPapaseit, Esther|||0000-0003-2620-4274Pérez-Mañá, Clara|||0000-0001-6343-6918Langohr, Klaus|||0000-0001-7075-9192Barbuti, MargheritaFarré Albaladejo, Magí|||0000-0001-8338-7543Torrens, MartaDepressionCocaine use disorderCortisolDual diagnosisBrain derived neurotrophic factor (BDNF)Major depressive disorder (MDD) and cocaine use disorder (CUD) are related with disability and high mortality rates. The assessment and treatment of psychiatric comorbidity is challenging due to its high prevalence and its clinical severity, mostly due to suicide rates and the presence of medical comorbidities. The aim of this study is to investigate differences in brain derived neurotrophic factor (BDNF) and cortisol plasmatic levels in patients diagnosed with CUD-primary-MDD and CUD-induced-MDD and also to compare them to a sample of MDD patients (without cocaine use), a sample of CUD (without MDD), and a group of healthy controls (HC) after a stress challenge. A total of 46 subjects were included: MDD (n = 6), CUD (n = 15), CUD-primary-MDD (n = 16), CUD-induced-MDD (n = 9), and 21 HC. Psychiatric comorbidity was assessed with the Spanish version of the Psychiatric Research Interview for Substance and Mental Disorders IV (PRISM-IV), and depression severity was measured with the Hamilton Depression Rating Scale (HDRS). Patients were administered the Trier Social Stress Test (TSST) before and after the biological measures, including BDNF, and cortisol levels were obtained. After the TSST, Cohen's d values between CUD-primary-MDD and CUD-induced-MDD increased in each assessment from 0.19 post-TSST to 2.04 post-90-TSST. Pairwise differences among CUD-induced-MDD and both MDD and HC groups had also a large effect size value in post-30-TSST and post-90-TSST. In the case of the BDNF concentrations, CUD-primary-MDD and CUD-induced-MDD in post-90-TSST (12,627.27 ± 5488.09 vs.17,144.84 ± 6581.06, respectively) had a large effect size (0.77). Results suggest a different pathogenesis for CUD-induced-MDD with higher levels of cortisol and BDNF compared with CUD-primary-MDD. Such variations should imply different approaches in treatment. 22022-01-0120222022-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/258138https://dx.doi.org/urn:doi:10.3389/fpsyt.2022.836771reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI09/02121Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI12/01838Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 PI16/00603Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 RD16/0017/0003Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 RD16/0017/0010Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 JR16/00020Ministerio de Sanidad, Servicios Sociales e Igualdad https://doi.org/10.13039/501100003751 2012I054Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 MTM2015-64465-C2-1-RAgència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2017/SGR-316Agència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2017/SGR-530open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2581382026-06-06T12:50:31Z
dc.title.none.fl_str_mv BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression
title BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression
spellingShingle BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression
Fonseca, Francina|||0000-0002-0779-6545
Depression
Cocaine use disorder
Cortisol
Dual diagnosis
Brain derived neurotrophic factor (BDNF)
title_short BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression
title_full BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression
title_fullStr BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression
title_full_unstemmed BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression
title_sort BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression
dc.creator.none.fl_str_mv Fonseca, Francina|||0000-0002-0779-6545
Mestre-Pintó, Joan-Ignasi|||0000-0003-0387-9375
Rodríguez-Minguela, Rocío
Papaseit, Esther|||0000-0003-2620-4274
Pérez-Mañá, Clara|||0000-0001-6343-6918
Langohr, Klaus|||0000-0001-7075-9192
Barbuti, Margherita
Farré Albaladejo, Magí|||0000-0001-8338-7543
Torrens, Marta
author Fonseca, Francina|||0000-0002-0779-6545
author_facet Fonseca, Francina|||0000-0002-0779-6545
Mestre-Pintó, Joan-Ignasi|||0000-0003-0387-9375
Rodríguez-Minguela, Rocío
Papaseit, Esther|||0000-0003-2620-4274
Pérez-Mañá, Clara|||0000-0001-6343-6918
Langohr, Klaus|||0000-0001-7075-9192
Barbuti, Margherita
Farré Albaladejo, Magí|||0000-0001-8338-7543
Torrens, Marta
author_role author
author2 Mestre-Pintó, Joan-Ignasi|||0000-0003-0387-9375
Rodríguez-Minguela, Rocío
Papaseit, Esther|||0000-0003-2620-4274
Pérez-Mañá, Clara|||0000-0001-6343-6918
Langohr, Klaus|||0000-0001-7075-9192
Barbuti, Margherita
Farré Albaladejo, Magí|||0000-0001-8338-7543
Torrens, Marta
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Depression
Cocaine use disorder
Cortisol
Dual diagnosis
Brain derived neurotrophic factor (BDNF)
topic Depression
Cocaine use disorder
Cortisol
Dual diagnosis
Brain derived neurotrophic factor (BDNF)
description Major depressive disorder (MDD) and cocaine use disorder (CUD) are related with disability and high mortality rates. The assessment and treatment of psychiatric comorbidity is challenging due to its high prevalence and its clinical severity, mostly due to suicide rates and the presence of medical comorbidities. The aim of this study is to investigate differences in brain derived neurotrophic factor (BDNF) and cortisol plasmatic levels in patients diagnosed with CUD-primary-MDD and CUD-induced-MDD and also to compare them to a sample of MDD patients (without cocaine use), a sample of CUD (without MDD), and a group of healthy controls (HC) after a stress challenge. A total of 46 subjects were included: MDD (n = 6), CUD (n = 15), CUD-primary-MDD (n = 16), CUD-induced-MDD (n = 9), and 21 HC. Psychiatric comorbidity was assessed with the Spanish version of the Psychiatric Research Interview for Substance and Mental Disorders IV (PRISM-IV), and depression severity was measured with the Hamilton Depression Rating Scale (HDRS). Patients were administered the Trier Social Stress Test (TSST) before and after the biological measures, including BDNF, and cortisol levels were obtained. After the TSST, Cohen's d values between CUD-primary-MDD and CUD-induced-MDD increased in each assessment from 0.19 post-TSST to 2.04 post-90-TSST. Pairwise differences among CUD-induced-MDD and both MDD and HC groups had also a large effect size value in post-30-TSST and post-90-TSST. In the case of the BDNF concentrations, CUD-primary-MDD and CUD-induced-MDD in post-90-TSST (12,627.27 ± 5488.09 vs.17,144.84 ± 6581.06, respectively) had a large effect size (0.77). Results suggest a different pathogenesis for CUD-induced-MDD with higher levels of cortisol and BDNF compared with CUD-primary-MDD. Such variations should imply different approaches in treatment.
publishDate 2022
dc.date.none.fl_str_mv 2
2022-01-01
2022
2022-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/258138
https://dx.doi.org/urn:doi:10.3389/fpsyt.2022.836771
url https://ddd.uab.cat/record/258138
https://dx.doi.org/urn:doi:10.3389/fpsyt.2022.836771
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI09/02121
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI12/01838
Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 PI16/00603
Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 RD16/0017/0003
Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 RD16/0017/0010
Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 JR16/00020
Ministerio de Sanidad, Servicios Sociales e Igualdad https://doi.org/10.13039/501100003751 2012I054
Ministerio de Economía y Competitividad https://doi.org/10.13039/501100003329 MTM2015-64465-C2-1-R
Agència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2017/SGR-316
Agència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2017/SGR-530
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406132437516288
score 15.300724

Similares en LA Referencia